I also truly believe there was a mistake somewhere and once it is corrected this goes to $12+ then $20 and $30 on approval. MC very low and retailers will rush in to buy, Big money is currently accumulating this low float and low MC bio!
Very doubtful that there was an error in the analysis. If there was then it would be hell to pay for the DMC that analyzed the data. If there are inconsistent results across sites then this may be a result of the execution of the trial or design. Again, this would be difficult to tease out and communicate effectively. After how Jan 31 went I am skeptical about management's ability to regain investor confidence. Personally, I am ticked for not selling all of my position out prior to results. Never a good idea to hold into results especially with a cancer trial.